Clinical trials: Demyelinating Disorder
Multiple Sclerosis
A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis
The purpose of this study was to assess the efficacy of Sativex in relieving symptoms of spasticity in multiple sclerosis
- Trial name
- NCT01599234
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 337 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis
Does Microglial Activation Promote Lesion Growth and Progression Among Multiple Sclerosis Patients
The purpose of this study is to assess whether increased microglial activation (measured using TSPO-PET) at lesion rim is associated with more rapid lesion growth during 10 year follow up.
- Trial name
- FUP-MS (NCT04625049)
- Where
- Finland
- Volunteers
- 100 people
- Sponsor
- Turku University Hospital
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
The purpose of the study is to assess the efficacy, safety, and tolerability of two doses of laquinimod compared to Avonex®
- Trial name
- LIBRETTO (NCT01975298)
- Testing
- Laquinimod, Avonex®
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years
This is an observational, non comparative, non-randomised, open-label, retrospective, single centre study planned to collect the data of subjects diagnosed with multiple sclerosis (MS) as per Poser or McDonald criteria between…
- Trial name
- NCT01084798
- Where
- Taiwan
- Volunteers
- 123 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
CONNECT Trial of eSupport Online Health-coach Moderated Support Groups for Multiple Sclerosis
Within-subject waitlist-control group design trial of eSupport health-coach moderated online support group participation to address mental health needs in persons with multiple sclerosis (PwMS) from historically underrepresented…
- Trial name
- CONNECT (NCT04943887)
- Testing
- eSupport Health Weekly Group Sessions for PwMS
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- eSupport Health
Prediction of Disease Progression, Multiple Sclerosis
Disease Progression in ms
Demographic and clinical data will be obtained from people with MS. Based on this data, the progression of the disease will be predicted with artificial intelligence.
- Trial name
- NCT07292116
- Volunteers
- 53 people
- Sponsor
- Hüseyin Bektaş
Multiple Sclerosis
Assessment of NfL and GFAP Levels, Atrophy of the Macula GCC by OCT and Whole Brain Atrophy by MRI to Predict Evolution of Neurological Disability in MS Patients
The investigators hypothesize that serum neurofilament-light chain (NfL) levels at baseline and decrease of the macular ganglion cell complex (GCC) thickness at one year vs.
- Trial name
- NFL OCT (NCT04860947)
- Testing
- Brain MRI, Spinal Cord MRI, Retinal imaging
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Multiple Sclerosis, Paralytic Stroke
Effect of I-TRAVLE Training on Arm Function in MS and Chronic Stroke Patients
Rationale: Approx. 80% of acute stroke patients suffer from acute hemiparesis. Stroke patients have not reached their full potential when they are discharged from hospital.
- Trial name
- NCT01918748
- Testing
- Haptic Master
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 30 people
- Sponsor
- Hasselt University
Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Cladribine Tablets as an Exit Therapy Strategy
The objective of the study is to evaluate the effectiveness of CladT, in terms of disease stability and safety, as the last treatment option in ageing MS patients vs treatment continuation and discontinuation This observational…
- Conditions
- Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- CLADREXIT (NCT06887426)
- Testing
- Cladribine
- Where
- France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Strasbourg, France
Multiple Sclerosis
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
The primary objective of this expanded access program is to provide ocrelizumab as treatment for eligible participants with primary progressive multiple sclerosis (PPMS) before it is commercially available in the United States…
- Trial name
- NCT02807285
- Testing
- Ocrelizumab
- Where
- 56 sites in United States
- Sponsor
- Genentech, Inc.
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019
The primary objective of the study is to assess the safety and tolerability of long-term treatment with BIIB019 (Daclizumab High Yield Process; DAC HYP) monotherapy in participants with relapsing remitting multiple sclerosis…
- Trial name
- EXTEND (NCT01797965)
- Testing
- BIIB019 (Daclizumab)
- Where
- 222 sites in United States, Argentina and 25 more
- Volunteers
- 1,501 people
- Sponsor
- Biogen
Multiple Sclerosis
The Effects of Focal Vibration on Spasticity in Multiple Sclerosis Patients
This trial consists of application of little devices (named Equistasi®) generating focal vibrations to treat spasticity in neurological patients, affected by multiple sclerosis.
- Trial name
- NCT02848898
- Testing
- Equistasi
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Federico II University
Multiple Sclerosis
Diagnostic Study of Quantitative Imaging and Spectroscopy in Patients With Multiple Sclerosis
OBJECTIVES: I. Determine by quantitative magnetic resonance imaging measurements the change in the total volume of brain parenchyma as well as its gray and white matter, T2 and enhanced T1 lesion volume, and the magnetization…
- Trial name
- NCT00006060
- Testing
- standard gadolinium contrast
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
X-linked Adrenoleukodystrophy
Quality of Life in Women With X-linked Adrenoleukodystrophy
X-linked adrenoleukodystrophy (X-ALD) is a hereditary white matter disorder caused by mutations in the ABCD1 gene leading to disturbances in the metabolism of fatty acids.
- Trial name
- X-ALD_QoL (NCT04675749)
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Leipzig University Medical Center
Primary Progressive Multiple Sclerosis, Primary Progressive MS
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
- Conditions
- Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS)
- Trial name
- NCT07840326
- Testing
- SUN-627
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sundance Biosciences, Inc.
Fatigue in Multiple Sclerosis
Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis
This study evaluated the effect of an individualized web-based physical training in fingolimod -treated patients.
- Trial name
- PACE (NCT01490840)
- Testing
- Physical exercise
- Where
- 32 sites in Germany
- Volunteers
- 178 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis
International multicenter, randomized, double-blind, double-masked, placebo-controlled study of efficacy and safety of BCD-132 (JSC BIOСAD, Russia) using an active reference drug (teriflunomide) for the treatment of patients with…
- Trial name
- NCT04056897
- Testing
- BCD-132, 125 mg, Teriflunomide, BCD-132, 500 mg
- Where
- Russia
- Volunteers
- 271 people
- Sponsor
- Biocad
Multiple Sclerosis
Multiple Sclerosis Produces Cardiovascular Subclinical Dysfunction
Multiple sclerosis (MS), debilitating disease involving primarily the central nervous system, may cause cardiovascular dysfunction, due to autonomous nervous system dysfunction, physical invalidity, increased oxidative stress…
- Trial name
- NCT03001284
- Testing
- NO intervention
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Carol Davila University of Medicine and Pharmacy
Multiple Sclerosis
A Study of the MIND Diet for Persons With Multiple Sclerosis
This study will assess the impact of a MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet on brain health and MS symptoms.
- Trial name
- NCT06992115
- Testing
- Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diet, Small Group
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Acute Demylelinating Optic Neuritis
Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)
To evaluate the efficacy and safety of fingolimod 0.5mg versus placebo in patients with suspected acute demyelinating optic neuritis (ADON) receiving standard steroid treatment
- Trial name
- NCT01757691
- Testing
- Fingolimod 0.5mg/daily
- Where
- 2 sites in United States, Spain
- Volunteers
- 2 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.